TY - JOUR
T1 - The Treatment of Venous Thromboembolism in the Emergency Department in the DOACs Era
AU - Osman, Ibrahim
AU - Atamna, Alaa
AU - Elis, Avishay
N1 - Publisher Copyright:
© 2023 Israel Medical Association. All rights reserved.
PY - 2023
Y1 - 2023
N2 - Background: Low-risk venous thromboembolism (VTE) patients are advised to be discharged from the emergency department (ED) on direct oral anticoagulants (DOACs) treatment. No data are available on whether this recommendation is followed in Israel. Objectives: To characterize newly diagnosed VTE patients who were discharged from the ED, their anticoagulation treatment at the ED, the recommended discharge protocol, and patient adherence. Methods: We conducted a retrospective cohort study, which included all newly diagnosed VTE patients who were discharged from the ED. Collected data included demographic and clinical background, anticoagulation treatment at the ED, recommended discharge protocol, patient subsequent adherence, recommended hematological evaluation, and adverse events. Results: The study group included 443 patients, 89% with deep vein thrombosis (DVT). Approximately three-quarters were treated with anticoagulants in the ED, 98% with enox-aparin. At discharge, anticoagulants were recommended for all; 49% continued enoxaparin, 47% DOACs, and 4% warfarin. After 4 weeks, 67% were treated with DOACs, 22% with enoxaparin, and 5% with warfarin. Approximately 6% discontinued all treatment. After 12 weeks, 90% of the patients who were taking DOACs adhered to the protocol, whereas only 70% and 50% among the enoxaparin and warfarin users, respectively, did. Only 56% were referred for hematological evaluation. The 12-week rate of adverse reactions was approximately 2%. The use of DOACs and the recommendation for further hematological evaluation increased over time. Conclusions: Clinician training regarding discharge of VTE patients from the ED should continue.
AB - Background: Low-risk venous thromboembolism (VTE) patients are advised to be discharged from the emergency department (ED) on direct oral anticoagulants (DOACs) treatment. No data are available on whether this recommendation is followed in Israel. Objectives: To characterize newly diagnosed VTE patients who were discharged from the ED, their anticoagulation treatment at the ED, the recommended discharge protocol, and patient adherence. Methods: We conducted a retrospective cohort study, which included all newly diagnosed VTE patients who were discharged from the ED. Collected data included demographic and clinical background, anticoagulation treatment at the ED, recommended discharge protocol, patient subsequent adherence, recommended hematological evaluation, and adverse events. Results: The study group included 443 patients, 89% with deep vein thrombosis (DVT). Approximately three-quarters were treated with anticoagulants in the ED, 98% with enox-aparin. At discharge, anticoagulants were recommended for all; 49% continued enoxaparin, 47% DOACs, and 4% warfarin. After 4 weeks, 67% were treated with DOACs, 22% with enoxaparin, and 5% with warfarin. Approximately 6% discontinued all treatment. After 12 weeks, 90% of the patients who were taking DOACs adhered to the protocol, whereas only 70% and 50% among the enoxaparin and warfarin users, respectively, did. Only 56% were referred for hematological evaluation. The 12-week rate of adverse reactions was approximately 2%. The use of DOACs and the recommendation for further hematological evaluation increased over time. Conclusions: Clinician training regarding discharge of VTE patients from the ED should continue.
KW - anticoagulation
KW - direct oral anticoagulants (DOACs)
KW - emergency department (ED)
KW - enoxaparin
KW - venous thromboembolism (VTE)
UR - http://www.scopus.com/inward/record.url?scp=85177429940&partnerID=8YFLogxK
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 37980618
AN - SCOPUS:85177429940
SN - 1565-1088
VL - 25
SP - 734
EP - 740
JO - Israel Medical Association Journal
JF - Israel Medical Association Journal
IS - 11
ER -